In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

Agathos records first sale of recombinant adeno-associated virus produced using AE1-BHK to collaborator Genovac; provides free access to AE1-BHK cell line FARGO, N.D.--(BUSINESS WIRE)--Agathos ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...

PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

MADISON, Wis., Aug. 11, 2021 /PRNewswire/ -- Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion to the existing ...

To generate successful gene therapies that are capable of delivering nucleic acids to specific cells and tissues, scientists must carefully design their products. They can employ either recombinant ...

In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...